- Home
- SUNS vs PBYI Comparison
SUNS vs PBYI Comparison
Compare SUNS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNS
- PBYI
- Stock Information
- Founded
- SUNS 2023
- PBYI 2010
- Country
- SUNS United States
- PBYI United States
- Employees
- SUNS N/A
- PBYI N/A
- Industry
- SUNS Real Estate Investment Trusts
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SUNS Real Estate
- PBYI Health Care
- Exchange
- SUNS Nasdaq
- PBYI Nasdaq
- Market Cap
- SUNS 148.2M
- PBYI 154.1M
- IPO Year
- SUNS N/A
- PBYI N/A
- Fundamental
- Price
- SUNS $11.07
- PBYI $2.98
- Analyst Decision
- SUNS Strong Buy
- PBYI Strong Buy
- Analyst Count
- SUNS 3
- PBYI 1
- Target Price
- SUNS $13.92
- PBYI $7.00
- AVG Volume (30 Days)
- SUNS 177.6K
- PBYI 386.8K
- Earning Date
- SUNS 03-06-2025
- PBYI 05-01-2025
- Dividend Yield
- SUNS 8.67%
- PBYI N/A
- EPS Growth
- SUNS N/A
- PBYI 37.78
- EPS
- SUNS 1.00
- PBYI 0.62
- Revenue
- SUNS $10,588,270.00
- PBYI $230,468,000.00
- Revenue This Year
- SUNS $141.80
- PBYI N/A
- Revenue Next Year
- SUNS $53.98
- PBYI $3.27
- P/E Ratio
- SUNS $10.71
- PBYI $4.83
- Revenue Growth
- SUNS 1342.10
- PBYI N/A
- 52 Week Low
- SUNS $8.11
- PBYI $2.23
- 52 Week High
- SUNS $15.74
- PBYI $6.06
- Technical
- Relative Strength Index (RSI)
- SUNS N/A
- PBYI 39.26
- Support Level
- SUNS N/A
- PBYI $3.14
- Resistance Level
- SUNS N/A
- PBYI $3.18
- Average True Range (ATR)
- SUNS 0.00
- PBYI 0.20
- MACD
- SUNS 0.00
- PBYI -0.06
- Stochastic Oscillator
- SUNS 0.00
- PBYI 4.38
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.